Table 3 Subgroup analysis and meta regression of pooled HRs for OS in cancer patients with increased HOXA11-AS expression
Subgroup analysis | No. of studies | No. of patients | Pooled HR (95% CI) | Meta regression (p value) | Heterogeneity | |
|---|---|---|---|---|---|---|
I2 | p value | |||||
Region | ||||||
 China | 5 | 349 | 2.31 (1.29–4.13) |  | 78.9% | 0.001 |
 Other | 3 | 971 | 1.90 (1.05–3.42) | 0.677 | 76.5% | 0.005 |
Sample size | ||||||
 ≥ 100 | 2 | 879 | 1.69 (0.89–3.21) |  | 76.8% | 0.013 |
 < 100 | 6 | 441 | 2.37 (1.40–4.02) | 0.469 | 78% | < 0.001 |
Preoperative treatment | ||||||
 No | 5 | 436 | 2.28 (1.68–3.10) |  | 0.4% | 0.404 |
 Unclear | 3 | 884 | 1.32 (0.99–1.76) | 0.187 | 71.8% | 0.014 |
NOS score | ||||||
 ≥ 7 | 5 | 430 | 2.26 (1.67–2.98) |  | 0 | 0.506 |
 < 7 | 3 | 890 | 1.77 (1.32–2.37) | 0.238 | 74.1% | 0.009 |